NADIM
Regimen
- Experimental
- neoadjuvant nivo + paclitaxel + carbo
- Control
- none
Population
Resectable stage IIIA NSCLC
Key finding
MPR 83%, pCR 63% in resected; 24-mo PFS 77.1%; generator hypothesis signal
Source: PMID 32979984
Timeline
- Enrollment start: 2017-04-15 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.165)